Zacks Investment Research downgraded shares of Cogentix Medical (NASDAQ:CGNT) from a buy rating to a hold rating in a research report released on Wednesday.
According to Zacks, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York. “
Other equities analysts have also recently issued research reports about the stock. TheStreet raised shares of Cogentix Medical from a d+ rating to a c rating in a research note on Thursday, November 9th. Roth Capital initiated coverage on shares of Cogentix Medical in a report on Wednesday, November 8th. They issued a buy rating and a $4.00 target price for the company. JMP Securities initiated coverage on shares of Cogentix Medical in a report on Friday, October 6th. They issued an outperform rating and a $5.00 target price for the company. Finally, Aegis initiated coverage on shares of Cogentix Medical in a report on Friday, December 1st. They set a buy rating and a $4.75 price target for the company. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $4.06.
A number of institutional investors and hedge funds have recently bought and sold shares of CGNT. Broadfin Capital LLC raised its holdings in Cogentix Medical by 45.2% during the 2nd quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock worth $1,905,000 after purchasing an additional 340,771 shares during the last quarter. Renaissance Technologies LLC boosted its position in Cogentix Medical by 2.3% during the 1st quarter. Renaissance Technologies LLC now owns 562,996 shares of the medical device company’s stock worth $1,013,000 after acquiring an additional 12,459 shares during the last quarter. Northern Trust Corp boosted its position in Cogentix Medical by 0.4% during the 2nd quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock worth $129,000 after acquiring an additional 326 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Cogentix Medical during the 3rd quarter worth approximately $152,000. Hedge funds and other institutional investors own 13.31% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Cogentix Medical (CGNT) Cut to “Hold” at Zacks Investment Research” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/24/cogentix-medical-cgnt-cut-to-hold-at-zacks-investment-research.html.
About Cogentix Medical
Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cogentix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical and related companies with MarketBeat.com's FREE daily email newsletter.